Document Detail

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
Jump to Full Text
MedLine Citation:
PMID:  21994136     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND AIMS: The standard treatment regimen for chronic HCV genotype 3 (HCV-G3) hepatitis consists of PEGylated interferon-α (IFN-α) and ribavirin at varying doses ranging from 400 to 1,200 mg and results in response rates of 80%. However, this therapy has substantial side-effects including anemia, is teratogenic, and costly. To reduce the side-effects of therapy, the role of monotherapy consisting of only IFN-α was investigated.
METHODS: A retrospective analysis of individual therapy courses of HCV-G3-infected patients who were treated with IFN-α(2a) monotherapy or a combination therapy with attention to the treatment outcome and the presence of IL28B rs12979860 and IL28B rs8099917 single-nucleotide polymorphism genotypes was performed. Conventional prognostic features in each case were assessed as well.
RESULTS: In the study, 15/30 (50%) of patients treated with IFN-α(2a) monotherapy and 32/36 (89%) treated with combination therapy achieved a sustained virological response (SVR). In addition, 7/11 (64%) of those treated initially with monotherapy and subsequently with combination therapy achieved an SVR. An "ultra-rapid" virological response occurring within 2 weeks of initiation of therapy (p = 0.005), young age (<40; p < 0.001) and low initial γ-GT/ALT-ratio (p = 0.03) were associated with a SVR to IFN-α(2a) monotherapy. An SVR in those treated with combination therapy was found to be associated with a rapid virological response (RVR) (p = 0.03). The absence of histologic steatosis was associated with SVR in all patient groups (p = 0.01). Therapy duration (24 vs. 48 weeks) did not affect the SVR in either group. As expected, combination therapy resulted in more hematological side-effects than did monotherapy.
CONCLUSIONS: An "ultra-rapid" virological response, young age, low initial γ-GT/ALT-ratio and absence of steatosis were each associated with an SVR in those receiving IFN-α(2a) monotherapy. Therefore, monotherapy in these patients should still be discussed independently of the existence of the IL28B polymorphisms.
Ahmad Amanzada; Armin Goralczyk; Federico Moriconi; Martina Blaschke; Inga-Marie Schaefer; David van Thiel; Sabine Mihm; Giuliano Ramadori
Related Documents :
18830786 - Sleeve gastrectomy leads to helicobacter pylori eradication.
21937376 - Results of seton drainage and infliximab infusion for complex anal crohn's disease.
2453596 - Pyrazinamide as a part of combination therapy for bl and ll patients--a preliminary rep...
21914976 - Successful multidrug treatment of a pediatric patient with severe churg-strauss syndrom...
15744796 - Psychosocial treatment for opiate abuse and dependence.
18503896 - Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery ste...
Publication Detail:
Type:  Journal Article     Date:  2011-10-13
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  56     ISSN:  1573-2568     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-07     Completed Date:  2011-12-27     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3296-304     Citation Subset:  AIM; IM    
Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Alanine Transaminase / blood
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Fatty Liver / pathology,  virology
Hepacivirus / genetics*
Hepatitis C, Chronic / blood,  drug therapy*,  pathology,  virology
Interferon-alpha / therapeutic use*
Liver / pathology
Middle Aged
Polymorphism, Single Nucleotide
Recombinant Proteins / therapeutic use
Retrospective Studies
Ribavirin / therapeutic use
Young Adult
gamma-Glutamyltransferase / blood
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Recombinant Proteins; 36791-04-5/Ribavirin; 76543-88-9/interferon alfa-2a; EC; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Dig Dis Sci
ISSN: 0163-2116
ISSN: 1573-2568
Publisher: Springer US, Boston
Article Information
Download PDF
© The Author(s) 2011
Received Day: 11 Month: 7 Year: 2011
Accepted Day: 21 Month: 9 Year: 2011
Electronic publication date: Day: 13 Month: 10 Year: 2011
pmc-release publication date: Day: 13 Month: 10 Year: 2011
Print publication date: Month: 11 Year: 2011
Volume: 56 Issue: 11
First Page: 3296 Last Page: 3304
ID: 3208815
PubMed Id: 21994136
Publisher Id: 1933
DOI: 10.1007/s10620-011-1933-2

Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy
Ahmad Amanzada1 Address:
Armin Goralczyk2 Address:
Federico Moriconi1 Address:
Martina Blaschke1 Address:
Inga-Marie Schaefer3 Address:
David van Thiel4 Address:
Sabine Mihm1 Address:
Giuliano Ramadori1 Address: +49-551-396301 +49-551-398596
1Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075 Göttingen, Germany
2General and Visceral Surgery, University Medical Center Göttingen, Göttingen, Germany
3Department of Pathology, University Medical Center Göttingen, Göttingen, Germany
4Division of Liver Disease, Rush University Medical Center, Chicago, IL USA


In the 1990s, chronic hepatitis C virus (HCV) infection began to be treated with an interferon alpha (IFN-α) monotherapy. Dependent on HCV genotype, viral load, IFN-α dose, and treatment duration, sustained virological response (SVR) rates of up to 55% could be achieved in patients with HCV non-1 genotypes [1]. Patients with HCV genotype 3 (HCV-G3) infection had SVR rates of 38% [2] to 67% [3] dependent of IFN-α dose. Studies that compared conventional IFN-α monotherapy to PEGylated interferon alpha (PEG-IFN-α) monotherapy achieved SVR rates of 28–46 and 38–68%, respectively [4, 5]. Furthermore, studies that compared the efficacy of the combination therapy of PEG-IFN-α or IFN-α and ribavirin (RBV) to monotherapy used IFN-α dose of 3 million units three times per week. SVR rates of patients with HCV-G3 were thus 21–32% [6, 7] for IFN-α and 38–45% for PEG-IFN-α [5, 8]. In subpopulations of HCV-G3 patients with low baseline viral load, 58% of those who were treated with PEG-IFN-α achieved SVR [8]. However, currently the standard treatment for patients with HCV-G3 is a combination therapy of PEG-IFN-α/RBV for 24 weeks attaining SVR rates of up to 80% [9]. Current recommendations for treatment of HCV genotype 2 or 3-infected patients are based on the result of a trial that compared 24–48 weeks of treatment with PEG-IFN-α/RBV [10]. Patients with HCV-G3 were treated with a schedule (RBV: 800 mg/day or 1,000/1,200 mg/day) similar to that of HCV genotype 1. A subsequent study of chronic HCV genotype 2 or 3-infected patients with PEG-IFN-α and 800 mg/day RBV but reduced duration [11] showed that SVR rates in a subpopulation of patients with low virus load and rapid virological response (RVR) were similar. Dalgard et al. [12] treated patients with chronic HCV-infected genotype 2 or 3 for 14 weeks with PEG-IFN-α and RBV 800 to 1,400 mg/day. SVR rates after 14 weeks of treatment were achieved more frequently among subtype 3a patients with low viral load and absence of bridging fibrosis/cirrhosis. A further study compared reduced doses of RBV (400 and 800 mg/day) for 24 weeks with equivalent outcomes in patients infected with HCV-G3 [13].

Interestingly, comparison of combination therapy with IFN-α monotherapy in patients with early virological response in HCV genotype 2 or 3 showed no significant differences with regard to the outcome [14]. Furthermore, two published studies showed acceptable SVR rates for patients with HCV genotype 2 or 3 after treatment with IFN-α monotherapy [15, 16]. Patients with virological response between 7 days and 2 weeks have the greatest chance of achieving an SVR.

Since the combination therapy with RBV increases the rate of side-effects, the discontinuation rate is more frequent [17]. The combination therapy is associated with a range of treatment-limiting serious adverse events in 4–9% in patients with HCV genotype 2 or 3 [11]. Patients’ hemoglobin concentration decreases under combination therapy with RBV significantly [18]. RBV-related anemia is an increased risk in patients with impaired renal dysfunction [19]. Because of the teratogenicity and the accumulation of RBV, contraception is strictly essential during and 6 months after therapy.

For these reasons, the current strategy for the treatment of chronic HCV infection is to individualize the treatment duration guided to HCV genotype and on-treatment viral response. Since the efficacy of therapy significantly depends on the virus genotype and on the host’s clinical, biochemical, and genetic background [20, 21], new therapeutic regimens have to be considered. Host genetic predictors for a successful therapy have been identified upstream of the interleukin 28B (IL28B)/IFN-λ3 gene. One single-nucleotide polymorphism (SNP), IL28B rs12979860, was independently and highly associated with SVR in patients with HCV genotype 1 [22]. In HCV genotype 2b patients who were treated with combination therapy, IL28B SNP rs8099917 was an independent factor for SVR, and, conversely, patients with HCV genotype 2a treated with IFN-α monotherapy, IL28B SNP rs8099917 was also an independent factor for SVR [23]. In patients with HCV-G3 treated with the combination therapy both IL28B-SNPs (rs12979860 and rs8099917) were not associated with SVR but with early virological response [24]. The impact of these two SNPs regarding combination therapy or IFN-α monotherapy has not been reported. Two subgroups of patients with HCV-G3 at our center who were treated either with combination therapy or IFN-α2a monotherapy provided the opportunity to assess the impact of the SNP rs12979860 and rs8099917 for SVR in addition to other clinical prognostic markers.

Materials and Methods

Sixty-six patients with chronic hepatitis C genotype 3 who were HCV-RNA-positive for more than 6 months were treated between 1994 and 2010. Thirty were treated with IFN-α2a monotherapy and 36 were treated with the standard combination therapy consisting of IFN-α and RBV. Eleven of 30 (50%) patients initially treated with IFN-α2a monotherapy did not achieve an SVR and were subsequently retreated with combination therapy. Disease chronicity was defined histopathologically by using established criteria [25]. In the patients who refused liver biopsy, chronicity was documented by longitudinal observation and the presence of advanced clinical liver disease. Inclusion criteria consisted of the following: (1) chronic hepatitis C by clinical criteria and/or histopathology, (2) HCV-antibody and HCV-RNA positivity, (3) genotype 3 infection. The exclusion criteria were decompensated liver disease, poorly controlled diabetes, clinically active autoimmune disorders, an elevated serum alpha-fetoprotein concentration, active alcohol or injection drug abuse, a history of major psychiatric disease, anemia (hemoglobin < 120 g/l), a reduced white blood cell (WBC) count (<3,000/μl) or thrombocytopenia (<50,000/μl), and pregnancy. In addition, the presence of active hepatitis A virus, human immunodeficiency virus, hepatitis B virus, cytomegalovirus, or an Epstein–Barr virus infection utilizing upon conventional laboratory diagnostic tests resulted in exclusion.

The study was approved by the local ethics committee and conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Informed written consent was obtained from all subjects.

Laboratory Procedures
Detection of Serum HCV-Specific RNA by RT-PCR

RNA was extracted from serum samples (140 μl) using the QIAamp Viral RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. One-fifth of the extracted material was subjected to a nested RT-PCR procedure as described [26].

Determination of HCV Genotypes

In HCV RNA-positive sera, virus genotyping was performed using the Innolipa HCV II line probe assay (Innogenetics, Ghent, Belgium).

Isolation of Genomic DNA

Genomic DNA was purified from peripheral blood mononuclear cells (PBMCs) through the use of the QIAamp DNA Mini Kit following the manufacturer’s blood and body fluid spin protocol (Qiagen). The concentration and the purity of the DNA isolated from PBMCs were determined photometrically by reading the absorbance levels at 260 and 280 nm. The integrity of genomic DNA was ascertained through electrophoresis using a 0.6% agarose gel.

Single-Nucleotide Polymorphism Genotyping by 5′-Nuclease Assay

Genomic DNA (5 ng derived from PBMCs or an aliquot corresponding to 16.7 μl serum) was amplified in a total volume of 20 μl by real-time PCR using the TaqMan Universal Master Mix (Applied Biosystems, Darmstadt, Germany) and 36 μmol/l at each primer in each case [IL28B rs rs12979860: forward, 5′-GCCTGTCGTGTACTGAACCA-3′; reverse 5′-GCGCGGAGTGCAATTCAAC-3′]. Allelic discrimination was achieved by adding 8 μmol/l differentially fluorescent dye-labeled allele-specific minor groove binder (MGB) probes (IL28B: VIC, 5′-TGGTTCGCGCCTTC-3′; FAM, 5′-CTGGTTCACGCCTTC-3′). IL28B rs8099917 was genotyped using a predesigned TaqMan SNP Genotyping Assay (Applied Biosystems; assay ID C__11710096_10). Reactions and analyses were carried out in the sequence detection system ABI prism step one plus (Applied Biosystems) according to the manufacturer’s instructions.

Treatment Regimens

IFN-α2a 3-6 Million Units (MU) (Roferon-A, F. Hoffmann-La Roche, Basel, Switzerland) was administered either daily or three times a week in those receiving monotherapy. PEG-IFN-α was administered once a week to those receiving combination therapy. Treatment was for 24 or 48 weeks, as treatment follow-up period of 48 weeks after the end of treatment (EOT) was utilized to define an SVR. All patients with an SVR were undetectable for HCV-RNA in serum 24 weeks and 48 weeks after the EOT. An “ultra-rapid” virological response was defined as serum HCV-RNA negativity at week 2. RVR was defined as undetectable serum HCV-RNA at week 4 of therapy.

Monitoring Procedures

Patients were assessed in an outpatient setting at weeks 2, 4, 6, 8, and every 4th week thereafter during treatment. Follow-up assessments were made at week 24 and 48 after EOT. Clinical examinations consisting of blood cell counts and routine biochemical tests were conducted at each clinic visit. Laboratory values were normalized by dividing the measurement by the upper limit of normal used as a continuous variable. HCV-RNA by RT-PCR was assessed at time zero and at week 2, 4, 12, 24, 36, and 48 during the 48-week treatment regimen and at time zero and weeks 2, 4, 12, and 24 for patients treated for 24 weeks. During the follow-up period, the presence of HCV-RNA in serum was assessed at week 24 and 48 after the EOT.

Histological Evaluation

Before starting therapy, liver biopsies for histological evaluation were taken from 51 (77%) patients. Sections (5–10 μm) from formalin-fixed and paraffin-embedded blocks were stained with hematoxylin and eosin (H&E), trichrome, and Prussian blue. Necroinflammatory activity (grading: score 1–3) and structural alterations (staging: scored 0–4) were scored separately according to Desmet et al. [27]. Other characteristic lesions of hepatitis C, such as the degree of steatosis (score 0–3) were reported and graded as described previously [25].

Statistical Analyses

Continuous and categorical variables were compared between the two groups by Wilcoxon Mann–Whitney test, χ2 test and Fisher’s exact test. A p value less than 0.05 was considered to be statistically significant. Hardy–Weinberg equilibrium calculations cited at were used as well. All statistical analyses were performed using the free available statistic program R cited at

Baseline Characteristics of the Patients

Data on 66 chronic HCV-infected patients (17 females, 49 males, mean age of 49 years, ranging from 23 to 61 years) were evaluated retrospectively with regard to the outcome of antiviral therapies and with regard to pretreatment serum enzymatic activities (AST, ALT, and γ-GT) and with regard to pre- and on-treatment hematological parameters (hemoglobin (Hb), and platelet and white blood cell (WBC) counts). Thirty (45%) naive patients had IFN-α2a monotherapy, 36 (55%) naive patients had definitive combination therapy, and 11 (37%) therapy experienced patients with initial IFN-α2a who were non-virological responder (non-SVR) were treated with combination therapy. Table 1 summarizes baseline demographic, biochemical, and virological characteristics of all patients with regard to different therapy regime. The two groups did not differ with regard to gender, age, HCV genotype, normalized AST, ALT, γ-GT activities, and hematological parameters nor IL28B genotype distributions or γ-GT/ALT ratio.

Genotyping of the two SNPs under investigation, IL28B rs12979860 and IL28B rs8099917, revealed distributions and minor allele frequencies (MAF) close to that given for Caucasians in public databases (IL28B rs12979860 CC:CT:TT 33:29:4 MAF 0.280, IL28B rs8099917 TT:TG:GG 49:16:1 MAF 0.136). For the patients as a whole, no deviation from Hardy–Weinberg equilibrium was found (IL28B rs12979860 p = 0.29 and IL28B rs8099917 p = 0.06).

Characteristics of Patients Treated with IFN-α2a Monotherapy

Fifteen of 30 (50%) patients treated with IFN-α2a achieved SVR. Factors found to be significantly associated with response were young age under 40 (p < 0.001), “ultrarapid” virological response within 2 weeks (p = 0.005), and low γ-GT/ALT-ratio (p = 0.03). Neither gender, HCV subtype, pre-treatment normalized AST, ALT, γ-GT levels, normalized hematological values, IL28B rs12979860 or IL28B rs8099917 genotypes nor therapy duration (24 weeks vs. 48 weeks) were found to be related to treatment outcome (Table 2).

Characteristics of Patients Treated with Combination Therapy

Thirty-nine of forty-seven (83%) patients with combination therapy achieved SVR. Only RVR (p = 0.03) as an on-treatment factor was associated with SVR, while neither gender, age, HCV subtype, pre-treatment normalized AST, ALT, γ-GT and pre-treatment, hematological values, therapy duration, nor IL28B rs12979860 or IL28B rs8099917 genotypes were associated with antiviral treatment outcome (Table 3). Evaluated hematological values until 12 weeks differed significantly with regard to response. Patients who developed anemia and thrombocytopenia within 8 weeks and leucopenia within 12 weeks during combination therapy showed association to SVR (data not shown). Patients under combination therapy also showed the development of pancytopenia within 12 weeks under the combination therapy.

Comparison of Hematological Values with Regard to Mono- or Combination Therapy

Further examinations were conducted to evaluate pre- and on-treatment hematological factors in terms of therapy regime. Hb levels of patients with monotherapy decreased but development of anemia could not be observed. Both therapy regimes caused thrombocytopenia and leucopenia but the combination therapy had a more pronounced effect. In comparison to monotherapy patients, under a combination therapy, pancytopenia developed (Table 4), but only decrease of Hb-N within 4 weeks and development of anemia at week 8 and 12 was significantly associated with combination therapy.

Evaluation of Histological Examinations for Outcome

Prior to treatment, 51 patients underwent histological examinations. These results were evaluated with regard to outcome independently of therapy regime. Only absence of steatosis (p = 0.01) was found to be associated with SVR, while neither the degree of hepatitis activity nor fibrosis stage were observed to be related to response (Table 5).


In this retrospective uncontrolled and monocentric study, the experience of 66 consecutive patients infected with genotype 3 HCV who received either IFN-α2a monotherapy (n = 19) or combination therapy consisting of PEG-IFN-α and RBV (n = 36) or both (n = 11), is reported. The patients were treated for either 24 or 48 weeks. Six months after the EOT, 54/67 patients (82%) had achieved a SVR; 15/30 (50%) responded to IFN-α2a monotherapy while 32/36 (89%) responded to combination therapy with an additional 11 of having initially received monotherapy achieved a SVR with combination therapy. Factors associated with an SVR whether assessed pre- or on-treatment with IFN-α2a monotherapy were age (<40), the development of “ultra-rapid” virological response occurring within 2 weeks of the initiation of therapy and a low initial γ-GT/ALT-ratio. Factors associated with an SVR with the combination therapy were an RVR, decreases of Hb, WBC count, platelet count, and the degree of steatosis. The nadir Hb value on combination therapy was significantly lower than that of IFN-α2a monotherapy group.

In chronically HCV-infected patients, SVR rates range up to 80% among patients infected with genotype 2 or 3 [9]. The therapeutic options for individuals with a genotype 3 infection are expanding. Recently, several studies have proposed new strategies for treatment of these patients. These include shortened duration of therapy [28, 29], a reduced dose of RBV and duration of therapy [30], and IFN-α2a monotherapy [16, 31]. These options for individuals infected with genotype 3 are of great interest because combination therapy has many side-effects, are teratogenic, and costly. Moreover, many individuals with a chronic HCV infection are of childbearing age and some have renal disease that makes the use of RBV difficult, if not impossible. As a result, individualized treatment options need to be considered and should be based upon recognized predictive factors for a SVR.

In recent years, many different factors predictive for a successful therapeutic outcome have been described. In addition to the HCV genotype [10], host-specific clinical, laboratory, and genetic factors [22, 26, 3234] have been recognized. Pre-treatment laboratory factors such as γ-GT/ALT-ratio [26, 34], AST to platelet ratio index (APRI) [24, 35], or clinical and histological factors [36] should also be considered in making a therapeutic decision.

In 2009, three different genome-wide association studies showed that various polymorphisms in the region of IL28B on chromosome 19 are highly associated with response in chronic HCV-genotype-1-infected patients after having sustained treatment with PEG-IFN-α and RBV therapy [22, 37, 38]. These polymorphisms of IL28B were associated with response in treatment-naive and non-responders of genotype-1-infected patients. Yu et al. [39] and Sakamoto et al. [40] investigated the role of IL28B in chronic HCV-genotype-2-infected patients after treatment with PEG-IFN-α and RBV. While Yu et al. [39] reported that the IL28B polymorphism did not predict a SVR but a RVR in HCV genotype 2 patients, Sakamoto et al. [40] reported that patients infected with genotype 2b with the major allele of IL28B showed increased SVR rates. Recently, Moghaddam et al. [24] examined the predictive ability of the IL28B polymorphism (rs12979860 and rs8099917) in patients with chronic HCV-G3 after treatment with combination therapy. They reported that these two SNPs are not predictive for a SVR. These results could be confirmed by Scherzer et al. [41] who suggested an association between IL28B polymorphisms and the early virological response to the application of a PEG-IFN-α and RBV therapy, but no effect was observed on SVR rates in HCV-G3 patients. In this study, we examined the predictive ability of the mentioned IL28B polymorphisms above with regard to monotherapy, but since the sample size of both groups are small, the statistical analysis of IL28B genetic distribution does not have enough power to reveal a significant outcome. However, rather, the findings of either a ultra rapid or RVR [24, 41] or a reduction in Hb [18] during therapy are associated with a SVR.

One of the reasons for the low response to standard IFN-α is its short half-life, which leads to wide fluctuations in the plasma concentration of the drug during the treatment period. Because HCV has a high rate of turnover [42], an intermittent increase in viral load can be observed in patients treated with standard IFN-α on treatment-free days [43]. Despite these disadvantages, Bjoro et al. [44] reported that in patients with genotype 2b/3a, low viral load and without cirrhosis the SVR rate could be increased by IFN-α induction (6 MU IFN-α2a daily for 4 weeks) up to 61%. Akuta et al. [45] and Yokosuka et al. [46] reported SVR rates of 68 and 84% in selected groups of chronic HCV-genotype-2 treated with induction IFN-α monotherapy. In these two studies, 6-10 MU IFN-α was administered daily for 2–4 weeks. The addition of a polyethylene glycol molecule to interferon produces a biologically active molecule with a longer half-life. This characteristic allows a more convenient dosing, i.e., once a week. In case of only applying PEG-IFN-α to patients with chronic HCV (all genotypes) for 48 weeks, the SVR rate was approximately twice (39%) as high as the rate of having applied standard IFN-α to the patients [5]. The subgroup analysis of the prospective randomized study by Fried et al. [8] showed that all HCV-G3 patients achieved SVR rates of 45% after PEG-IFN-α monotherapy. Another prospective randomized study by Angelico et al. [14] showed that selected groups of patients with HCV-genotype 2/3 had a SVR rate of 67% through the application of PEG-IFN-α therapy. Based upon these data, in patients infected with HCV-G3 who are young (<40 years), have a low viral load, histologically mild disease, and a low initial γ-GT/ALT-ratio, monotherapy with IFN-α is effective in 50% of the individuals treated. As mentioned above, considerable data on the use of PEG-IFN-α for the treatment of HCV-infected patients are available in the literature [8, 9]. In contrast, daily dosing of IFN-α consisting of 3 MU for 24 weeks has been reported to achieve a 66.7% SVR rate. The patients who achieved an SVR had an initial virological response after only 2 weeks of IFN-α2a monotherapy [16]. These data are in accordance with the present results and suggest that the adverse effects of RBV can be avoided in a subgroup of patients with HCV-G3 who show an “ultra-rapid” virological response within 2 weeks of the start of IFN-α treatment. Those who do not achieve an “ultra-rapid” virological response can have RBV added to their therapy to enhance the likelihood of their achieving an SVR. This approach would eliminate the potential teratogenic effects of RBV in patients, reduce the severity of the anemia occurring during therapy, and reduce the cost of therapy in those receiving monotherapy who achieve an “ultra-rapid” virological response.

It needs to be recognized that important limitations to the present report exist: (1) It is a retrospective study, which was placed on (2) a single center, (3), which included only a small sample size referring to each group, and (4) with different therapy regimes within the groups. This study contains an explorative analysis for further suggestions of different therapy regimes for chronic HCV-G3 patients. In order to examine the hypothesis of this retrospective study, a prospective trail should be initiated that should include the suggested criteria by starting PEG-IFN-α2a monotherapy in selected patients.

In conclusion, patients, who are under 40 years, having a low viral load and a low initial γ-GT/ALT-ratio, absence of fibrosis/cirrhosis and steatosis, and who develop an on-treatment “ultra-rapid” virological response can achieve an SVR of 50%. This subgroup of patients may benefit from a treatment regimen consisting of PEG-IFN-α monotherapy.

The authors wish to thank all the physicians in the Department of Gastroenterology and Endocrinology who were involved in the care and control of patients. The authors would also like to thank Ulrike Wegner, Jutta Blumberg, and Waltraut Kopp for their expert technical assistance. We wish to thank all the patients for allowing us to summarize the clinical data for publication.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

1.. Davis GL,Lau JY. Factors predictive of a beneficial response to therapy of hepatitis CHepatologyYear: 199726122S127S10.1002/hep.5102607219305676
2.. Chemello L,Bonetti P,Cavalletto L,Talato F,Donadon V,Casarin P,Belussi F,Frezza M,Noventa F,Pontisso P. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis GroupHepatologyYear: 1995227007067657272
3.. Martinot-Peignoux M,Marcellin P,Pouteau M,Castelnau C,Boyer N,Poliquin M,Degott C,Descombes I,Le B,Milotova V. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis CHepatologyYear: 1995221050105610.1002/hep.18402204067557850
4.. Lindsay KL,Trepo C,Heintges T,Shiffman ML,Gordon SC,Hoefs JC,Schiff ER,Goodman ZD,Laughlin M,Yao R,Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis CHepatologyYear: 20013439540310.1053/jhep.2001.2637111481625
5.. Zeuzem S,Feinman SV,Rasenack J,Heathcote EJ,Lai MY,Gane E,O’Grady J,Reichen J,Diago M,Lin A,Hoffman J,Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis CN Engl J MedYear: 20003431666167210.1056/NEJM20001207343230111106715
6.. McHutchison JG,Gordon SC,Schiff ER,Shiffman ML,Lee WM,Rustgi VK,Goodman ZD,Ling MH,Cort S,Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl J MedYear: 19983391485149210.1056/NEJM1998111933921019819446
7.. Reichard O,Norkrans G,Fryden A,Braconier JH,Sonnerborg A,Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study GroupLancetYear: 1998351838710.1016/S0140-6736(97)06088-19439491
8.. Fried MW,Shiffman ML,Reddy KR,Smith C,Marinos G,Goncales FL Jr,Haussinger D,Diago M,Carosi G,Dhumeaux D,Craxi A,Lin A,Hoffman J,J Yu. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J MedYear: 200234797598210.1056/NEJMoa02004712324553
9.. Manns MP,McHutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R,Goodman ZD,Koury K,Ling M,Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancetYear: 200135895896510.1016/S0140-6736(01)06102-511583749
10.. Hadziyannis SJ,Sette H Jr,Morgan TR,Balan V,Diago M,Marcellin P,Ramadori G,Bodenheimer H Jr,Bernstein D,Rizzetto M,Zeuzem S,Pockros PJ,Lin A,Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern MedYear: 200414034635514996676
11.. Shiffman ML,Suter F,Bacon BR,Nelson D,Harley H,Sola R,Shafran SD,Barange K,Lin A,Soman A,Zeuzem S. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3N Engl J MedYear: 200735712413410.1056/NEJMoa06640317625124
12.. Dalgard O,Bjoro K,Hellum KB,Myrvang B,Ritland S,Skaug K,Raknerud N,Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot studyHepatologyYear: 2004401260126510.1002/hep.2046715558712
13.. Ferenci P,Brunner H,Laferl H,Scherzer TM,Maieron A,Strasser M,Fischer G,Hofer H,Bischof M,Stauber R,Gschwantler M,Steindl-Munda P,Staufer K,Loschenberger K. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3HepatologyYear: 2008471816182310.1002/hep.2226218454510
14.. Angelico M,Koehler-Horst B,Piccolo P,Angelico F,Gentile S,Francioso S,Tarquini P,Vecchia RD,Ponti L,Pilleri G,Barlattani A,Grieco A,Soccorsi F,Guarascio P,Demelia L,Sorbello O,Rossi Z,Forlini G,Zaru S,Bandiera F. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis CEur J Gastroenterol HepatolYear: 20082068068710.1097/MEG.0b013e3282f5196c18679072
15.. Yada M,Masumoto A,Yamashita N,Motomura K,Koyanagi T,Sakamoto S. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis CWorld J GastroenterolYear: 2010161506151110.3748/wjg.v16.i12.150620333792
16.. Wietzke-Braun P,Meier V,Neubauer-Saile K,Mihm S,Ramadori G. Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patientsWorld J GastroenterolYear: 2005116188619216273648
17.. Kumada T,Toyoda H,Honda T,Kuzuya T,Katano Y,Nakano I,Goto H. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in JapanIntervirologyYear: 20064911211810.1159/00008727316166799
18.. Sievert W,Dore GJ,McCaughan GW,Yoshihara M,Crawford DH,Cheng W,Weltman M,Rawlinson W,Rizkalla B,Depamphilis JK,Roberts SK. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1HepatologyYear: 2011531109111710.1002/hep.2418021480317
19.. Reau N,Hadziyannis SJ,Messinger D,Fried MW,Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirinAm J GastroenterolYear: 20081031981198810.1111/j.1572-0241.2008.01957.x18796095
20.. Kinzie JL,Naylor PH,Nathani MG,Peleman RR,Ehrinpreis MN,Lybik M,Turner JR,Janisse JJ,Massanari M,Mutchnick MG. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than CaucasiansJ Viral HepatYear: 2001826426910.1046/j.1365-2893.2001.00292.x11454177
21.. Wietzke-Braun P,Maouzi AB,Manhardt LB,Bickeboller H,Ramadori G,Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infectionEur J Gastroenterol HepatolYear: 20061899199710.1097/01.meg.0000224478.89545.7616894313
22.. Ge D,Fellay J,Thompson AJ,Simon JS,Shianna KV,Urban TJ,Heinzen EL,Qiu P,Bertelsen AH,Muir AJ,Sulkowski M,McHutchison JG,Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNatureYear: 200946139940110.1038/nature0830919684573
23.. Kawaoka T,Hayes CN,Ohishi W,Ochi H,Maekawa T,Abe H,Tsuge M,Mitsui F,Hiraga N,Imamura M,Takahashi S,Kubo M,Tsunoda T,Nakamura Y,Kumada H,Chayama K. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2bJ HepatolYear: 20115440841410.1016/j.jhep.2010.07.03221112660
24.. Moghaddam A,Melum E,Reinton N,Ring-Larsen H,Verbaan H,Bjoro K,Dalgard O. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infectionHepatologyYear: 20115374675410.1002/hep.2415421374656
25.. Mihm S,Fayyazi A,Hartmann H,Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotypeHepatologyYear: 19972573573910.1002/hep.5102503409049227
26.. Mihm S,Hartmann H,Fayyazi A,Ramadori G. Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratioDig Dis SciYear: 1996411256126410.1007/BF020882468654161
27.. Desmet VJ,Gerber M,Hoofnagle JH,Manns M,Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and stagingHepatologyYear: 1994191513152010.1002/hep.18401906298188183
28.. Lagging M,Langeland N,Pedersen C,Farkkila M,Buhl MR,Morch K,Dhillon AP,Alsio A,Hellstrand K,Westin J,Norkrans G. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infectionHepatologyYear: 2008471837184510.1002/hep.2225318454508
29.. Wagner M,Huber M,Berg T,Hinrichsen H,Rasenack J,Heintges T,Bergk A,Bernsmeier C,Haussinger D,Herrmann E,Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis CGastroenterologyYear: 200512952252710.1053/j.gastro.2005.05.00816083709
30.. Manns M,Zeuzem S,Sood A,Lurie Y,Cornberg M,Klinker H,Buggisch P,Rossle M,Hinrichsen H,Merican I,Ilan Y,Mauss S,Abu-Mouch S,Horban A,Muller TH,Welsch C,Chen R,Faruqi R,Pedicone LD,Wedemeyer H. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis CJ HepatolYear: 20115555456310.1016/j.jhep.2010.12.02421237227
31.. Tsunoda T,Inui A,Etani Y,Kiyohara Y,Sugiura T,Ito K,Miyazawa R,Nagata I,Ida S,Fujisawa T. Efficacy of pegylated interferon-alpha2a monotherapy in Japanese children with chronic hepatitis CHepatol ResYear: 20114139940410.1111/j.1872-034X.2011.00789.x21518401
32.. Rodriguez-Torres M,Jeffers LJ,Sheikh MY,Rossaro L,Ankoma-Sey V,Hamzeh FM,Martin P. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis CN Engl J MedYear: 200936025726710.1056/NEJMoa080506219144941
33.. Liu CH,Liu CJ,Lin CL,Liang CC,Hsu SJ,Yang SS,Hsu CS,Tseng TC,Wang CC,Lai MY,Chen JH,Chen PJ,Chen DS,Kao JH. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trialClin Infect DisYear: 2008471260126910.1086/59257918834319
34.. Mihm S,Monazahian M,Grethe S,Fechner C,Ramadori G,Thomssen R. Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infectionJ Med VirolYear: 19995822723410.1002/(SICI)1096-9071(199907)58:3<227::AID-JMV7>3.0.CO;2-710447417
35.. Mata-Marin JA,Fuentes-Allen JL,Gaytan-Martinez J,Manjarrez-Tellez B,Chaparro-Sanchez A,Arroyo-Anduiza CI. APRI as a predictor of early viral response in chronic hepatitis C patientsWorld J GastroenterolYear: 2009154923492710.3748/wjg.15.492319842223
36.. Verbaan HP,Widell HE,Bondeson TL,Lindgren SC. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirinEur J Gastroenterol HepatolYear: 20021462763310.1097/00042737-200206000-0000712072596
37.. Suppiah V,Moldovan M,Ahlenstiel G,Berg T,Weltman M,Abate ML,Bassendine M,Spengler U,Dore GJ,Powell E,Riordan S,Sheridan D,Smedile A,Fragomeli V,Muller T,Bahlo M,Stewart GJ,Booth DR,George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyNat GenetYear: 2009411100110410.1038/ng.44719749758
38.. Tanaka Y,Nishida N,Sugiyama M,Kurosaki M,Matsuura K,Sakamoto N,Nakagawa M,Korenaga M,Hino K,Hige S,Ito Y,Mita E,Tanaka E,Mochida S,Murawaki Y,Honda M,Sakai A,Hiasa Y,Nishiguchi S,Koike A,Sakaida I,Imamura M,Ito K,Yano K,Masaki N,Sugauchi F,Izumi N,Tokunaga K,Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CNat GenetYear: 2009411105110910.1038/ng.44919749757
39.. Yu ML,Huang CF,Huang JF,Chang NC,Yang JF,Lin ZY,Chen SC,Hsieh MY,Wang LY,Chang WY,Li YN,Wu MS,Dai CY,Juo SH,Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patientsHepatologyYear: 20115371310.1002/hep.2397621254157
40.. Sakamoto N,Nakagawa M,Tanaka Y,Sekine-Osajima Y,Ueyama M,Kurosaki M,Nishida N,Tamori A,Yuki NS,Itsui Y,Azuma S,Kakinuma S,Hige S,Itoh Y,Tanaka E,Hiasa Y,Izumi N,Tokunaga K,Mizokami M,Watanabe M. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2bJ Med VirolYear: 20118387187810.1002/jmv.2203821360545
41.. Scherzer TM,Hofer H,Staettermayer AF,Rutter K,Beinhardt S,Steindl-Munda P,Kerschner H,Kessler HH,Ferenci P. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirinJ HepatolYear: 20115486687110.1016/j.jhep.2010.08.02421145807
42.. Neumann AU,Lam NP,Dahari H,Gretch DR,Wiley TE,Layden TJ,Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapyScienceYear: 199828210310710.1126/science.282.5386.1039756471
43.. Lam NP,Neumann AU,Gretch DR,Wiley TE,Perelson AS,Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfaHepatologyYear: 19972622623110.1002/hep.5102601309214474
44.. Bjoro K,Bell H,Myrvang B,Skaug K,Raknerud N,Sandvei P,Storseth S,Ritland S,Lund-Tonnesen S,Bucher A,Hellum KB. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre studyScand J GastroenterolYear: 20023734434910.1080/00365520231728426411916198
45.. Akuta N,Suzuki F,Tsubota A,Suzuki Y,Someya T,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Kumada H. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factorsJ HepatolYear: 20023783183610.1016/S0168-8278(02)00301-X12445425
46.. Yokosuka O,Iwama S,Suzuki N,Takashi M,Hirai Y,Uchiumi K,Kimura M,Gotou N,Hino S,Hayasaka A,Kanda T,Kawai S,Fukai K,Imazeki F,Saisho H. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective studyIntervirologyYear: 20044732833410.1159/00008087615564744

[TableWrap ID: Tab1] Table 1 

Baseline characteristics of chronic HCV-G3-infected patients provided with an IFN-α2a mono- or combination therapy

IFN-α2a mono-therapy (n = 30) Combination therapy (n = 36) p value
Gender (female/male) 10/20 7/29 0.32a
Mean age (years ± SD) 50.4 ± 9.5 47.8 ± 11.9 0.46b
HCV subtype (3a/3c) 22/8 26/10 0.99a
AST-N (mean ± SD) 1.18 ± 0.80 1.63 ± 1.25 0.07b
ALT-N (mean ± SD) 1.81 ± 1.27 2.46 ± 2.03 0.10b
γ-GT-N (mean ± SD) 0.81 ± 0.63 0.86 ± 0.74 0.33b
Hb-N (mean ± SD) 1.21 ± 0.09 1.16 ± 0.08 0.53b
Platelet × 103/μl (mean ± SD) 198 ± 48 215 ± 53 0.13b
WBC × 103/μl (mean ± SD) 6.69 ± 1.64 7.15 ± 1.88 0.24b
IL28B rs12979860 (CC:CT:TT) 13:14:3 (43%:47%:10%) 20:15:1 (55%:42%:3%) 0.37c
IL28B rs8099917 (TT:TG:GG) 19:10:1 (63%:33%:4%) 30:6:0 (83%:17%:0%) 0.14c
Low γ-GT/ALT-ratio 18 (60%) 28 (78%) 0.32a

N normalized

aFisher’s exact test

bWilcoxon Mann–Whitney test

cχ2 test

[TableWrap ID: Tab2] Table 2 

Comparison of pre- and on-treatment characteristics of chronic HCV-G3-infected patients treated with an IFN-α2a monotherapy with regard to therapy outcome

+SVR (n = 15) −SVR (n = 15) p value
Gender (female/male) 6/9 4/11 0.69a
Mean age (years ± SD) 38.4 ± 7.8 50.1 ± 9.5 <0.001b
HCV subtype (3a/3c) 11/4 11/4 1a
AST-N (mean ± SD) 0.97 ± 0.74 0.90 ± 0.41 0.52b
ALT-N (mean ± SD) 1.69 ± 1.66 1.33 ± 0.78 0.79b
γ-GT-N (mean ± SD) 0.74 ± 0.82 0.58 ± 0.44 0.84b
Hb-N (mean ± SD) 1.22 ± 0.11 1.19 ± 0.07 0.93b
Platelet × 103/μl (mean ± SD) 192 ± 45 203 ± 47 0.60b
WBC × 103/μl (mean ± SD) 6.12 ± 1.67 6.91 ± 1.42 0.08b
IL28B rs12979860 (CC:CT:TT) 6:9:0 (40%:60%:0%) 7:5:3 (47%:33%:20%) 0.12c
IL28B rs8099917 (TT:TG:GG) 11:4:0 (73%:27%:0%) 10:4:1 (67%:27%:6%) 0.48c
HCV neg. 2 week (ultra-rapid virological response) 12 (80%) 4 (27%) 0.005a
Low γ-GT/ALT 12 (80%) 6 (40%) 0.03a
Therapy duration/regime (weeks) 0.5a
 24 6 (40%) 5 (33%)
 48 9 (60%) 10 (67%)
IFN-α2a (dose)
 24 weeks (9–21 Mio/week) 0 4 (27%)
 24 weeks (18–42 Mio/week) 6 (40%) 1 (6%)
 48 weeks (9–42 Mio/week) 8 (54%) 10 (67%)
 48 weeks (PEG-IFN-α 180 μg/week) 1 (6%) 0

N normalized

aFisher’s exact test

bWilcoxon Mann–Whitney test

cχ2 test

[TableWrap ID: Tab3] Table 3 

Comparison of pre- and on-treatment characteristics of chronic HCV-G3-infected patients treated with a combination therapy with regard to therapy outcome

+SVR (n = 39) −SVR (n = 8) p value
Gender (female/male) 9/30 2/6 0.73a
Mean age (years ± SD) 49.3 ± 12.1 47.6 ± 7.5 0.15b
HCV subtype (3a/3c) 29/10 6/2 0.67a
AST-N (mean ± SD) 1.43 ± 1.19 1.64 ± 1.04 0.1b
ALT-N (mean ± SD) 2.35 ± 1.99 1.41 ± 0.96 0.23b
γ-GT-N (mean ± SD) 0.74 ± 0.59 0.91 ± 1.08 0.35b
Hb-N (mean ± SD) 1.18 ± 0.08 1.17 ± 0.09 0.25b
Platelet × 103/μl (mean ± SD) 214 ± 56 205 ± 38 0.42b
WBC × 103/μl (mean ± SD) 7.15 ± 1.85 6.81 ± 1.75 0.31b
IL28B rs12979860 (CC:CT:TT) 20:16:3 (51%:41%:8%) 4:3:1 (50%:38%:12%) 0.9c
IL28B rs8099917 (TT:TG:GG) 29:9:1 (74%:23%:3%) 7:1:0 (88%:12%:0%) 0.48c
RVR 31 (80%) 3 (38%) 0.03a
Low γ-GT/ALT-ratio 26 (74%) 4 (50%) 0.21a
Therapy duration/regime (weeks) 0.66a
 24 33 (85%) 7 (88%)
 48 6 (15%) 1 (12%)

N normalized

aFisher’s exact test

bWilcoxon Mann–Whitney test

cχ2 test

[TableWrap ID: Tab4] Table 4 

Comparison of hematological side-effects of IFN-α2a monotherapy and combination therapy

IFN-α2a mono-therapy (n = 30) Combination therapy (n = 36) p value
Hb-N (mean ± SD)
 Pre-treatment 1.21 (±0.09) 1.16 (±0.08) 0.53
 4 weeks 1.12 (±0.11) 1.02 (±0.11) 0.04
 8 weeks 1.07 (±0.11) 0.95 (±0.12) 0.005
 12 weeks 1.03 (±0.11) 0.91 (±0.11) 0.004
Platelet × 103/μl (mean ± SD)
 Pre-treatment 198 (±48) 216 (±53) 0.12
 4 weeks 157 (±45) 157 (±55) 0.96
 8 weeks 146 (±43) 130 (±46) 0.09
 12 weeks 142 (±45) 125 (±50) 0.08
WBC × 103/μl (mean ± SD)
 Pre-treatment 6.69 (±1.64) 7.22 (±1.88) 0.24
 4 weeks 4.23 (±1.73) 4.43 (±1.85) 0.86
 8 weeks 4.00 (±1.52) 4.09 (±3.78) 0.24
 12 weeks 3.91 (±1.53) 3.20 (±1.16) 0.06

Wilcoxon Mann–Whitney test was applied; N normalized

[TableWrap ID: Tab5] Table 5 

Histological features of chronic HCV-G3-infected with regard to outcome n (%)

+SVR (n = 40) −SVR (n = 11) p value
Hepatitis ns
 Mild 32 (80%) 8 (73%)
 Moderate 7 (18%) 2 (18%)
 Severe 1 (2%) 1(9%)
Fibrosis ns
 Absent 25 (63%) 5 (46%)
 Mild 11 (27%) 3 (27%)
 Moderate 0 0
 Marked 0 2 (18%)
 Cirrhosis 4 (10%) 1 (9%)
Steatosis 0.01
 Absent 20 (50%) 1 (9%)
 Mild 12 (30%) 6 (55%)
 Moderate 7 (18%) 4 (36%)
 Marked 1 (2%) 0

χ2 test was applied to compare SVR versus non-SVR with regard to hepatitis (mild vs. moderate or severe), to fibrosis (absent vs. mild, moderate, marked or cirrhosis), and to steatosis (absent vs. mild, moderate or marked)

Article Categories:
  • Original Article

Keywords: Keywords Chronic hepatitis C virus infection, Treatment, Monotherapy, Ribavirin.

Previous Document:  Ionic liquid-assisted SDS-PAGE to improve human serum protein separation.
Next Document:  Infectious Proctitis: When to Suspect It Is Not Inflammatory Bowel Disease.